Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phosphagenics Ltd.

www.phosphagenics.com

Latest From Phosphagenics Ltd.

ANI Pharmaceuticals Appoints New Board Member

ANI Pharmaceuticals Inc. has appointed Peter A. Lankau to its board of directors. Currently Lankau is on the board of advisors of Orchard Venture Partners and chair of the board at Phosphagenics Ltd. Prior to this, he was executive chair at Nautilus Neurosciences, Inc. and before this he was chair and CEO of Logical Therapeutics, Inc. Previously, he was CEO and director of Endo Pharmaceuticals Inc.

Companies

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Pain Easing For Aussie Phosphagenics After Phase I Results Follow CEO Fraud Allegations

After fraud allegations involving its chief executive, Phosphagenics reports promising Phase I results for its transdermal oxymorphone patch.

BioPharmaceutical Australia

Phosphagenics soars on Phase I oxymorphone patch results

It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
      • Transdermal
    • OTC, Consumer
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Phosphagenics Ltd.
  • Senior Management
  • Harry Rosen, CEO
    Anna Legg, CFO
    Paul Gavin, PhD, CSO
    Alex Stojanovic, PhD, VP, Bus. Dev. & Commercial Ops.
  • Contact Info
  • Phosphagenics Ltd.
    Phone: 3 9565 1119
    11 Duerdin St.
    P.O. Box 1415 Clayton, 3168
    Australia
UsernamePublicRestriction

Register